Zacks Research Has Positive View of Haemonetics Q1 Earnings

Haemonetics Corporation (NYSE:HAE) – Research analysts at Zacks Research upped their Q1 2028 EPS estimates for Haemonetics in a research report issued on Wednesday, January 28th. Zacks Research analyst Team now forecasts that the medical instruments supplier will post earnings per share of $1.39 for the quarter, up from their prior forecast of $1.38. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, topping the consensus estimate of $1.12 by $0.15. Haemonetics had a net margin of 12.67% and a return on equity of 27.22%. The firm had revenue of $327.32 million for the quarter, compared to analysts’ expectations of $311.61 million. During the same period in the previous year, the firm posted $1.12 EPS. The company’s revenue for the quarter was down 5.3% on a year-over-year basis. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS.

Several other research firms also recently commented on HAE. Robert W. Baird increased their price objective on Haemonetics from $87.00 to $99.00 and gave the company an “outperform” rating in a report on Monday, December 15th. Citigroup dropped their price target on shares of Haemonetics from $78.00 to $64.00 and set a “buy” rating on the stock in a research report on Tuesday, October 7th. BTIG Research restated a “buy” rating and set a $88.00 price objective on shares of Haemonetics in a research note on Friday, January 9th. Raymond James Financial reiterated an “outperform” rating and issued a $90.00 target price on shares of Haemonetics in a research note on Friday, November 14th. Finally, JPMorgan Chase & Co. boosted their price target on Haemonetics from $62.00 to $74.00 and gave the stock a “neutral” rating in a research report on Friday, December 12th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $84.40.

Haemonetics Stock Performance

Shares of NYSE HAE opened at $65.93 on Friday. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.03 and a current ratio of 1.64. The stock has a 50 day moving average price of $78.72 and a 200 day moving average price of $65.57. The stock has a market capitalization of $3.09 billion, a PE ratio of 19.28, a price-to-earnings-growth ratio of 1.37 and a beta of 0.29. Haemonetics has a 52 week low of $47.31 and a 52 week high of $87.32.

Institutional Trading of Haemonetics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. M&T Bank Corp increased its position in Haemonetics by 31.0% during the 4th quarter. M&T Bank Corp now owns 6,154 shares of the medical instruments supplier’s stock worth $494,000 after purchasing an additional 1,457 shares in the last quarter. Peregrine Capital Management LLC acquired a new position in shares of Haemonetics during the fourth quarter worth $2,293,000. Joseph P. Lucia & Associates LLC bought a new position in shares of Haemonetics in the 4th quarter valued at $650,000. Bayforest Capital Ltd acquired a new stake in shares of Haemonetics during the 4th quarter valued at $40,000. Finally, Merit Financial Group LLC bought a new stake in Haemonetics during the 4th quarter worth $282,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.